The massive French pharmaceutical company Sanofi announced that it is collaborating with artificial intelligence startups OpenAI and Formation Bio to boost its drug development ambitions using AI.
French pharmaceutical giant Sanofi (SASY.PA) stated on Tuesday that it is working with Formation Bio and OpenAI, an artificial intelligence company, to advance its drug research initiatives through the use of AI.
Sanofi said in a statement that Formation Bio will supply more engineering resources and that the collaboration with OpenAi will give it access to proprietary data to create AI models for its biopharma models.
Big pharmaceutical companies are utilizing artificial intelligence to discover clinical trial participants more quickly and to decrease the number of subjects required for medication testing, which might speed up drug development and save millions of dollars.
Also read: Unveiling the Ethical Imperatives: Navigating the Intersection of AI and Cybersecurity
Do Follow: CIO News LinkedIn Account | CIO News Facebook | CIO News Youtube | CIO News Twitter
About us:
CIO News is the premier platform dedicated to delivering the latest news, updates, and insights from the CIO industry. As a trusted source in the technology and IT sector, we provide a comprehensive resource for executives and professionals seeking to stay informed and ahead of the curve. With a focus on cutting-edge developments and trends, CIO News serves as your go-to destination for staying abreast of the rapidly evolving landscape of technology and IT. Founded in June 2020, CIO News has rapidly evolved with ambitious growth plans to expand globally, targeting markets in the Middle East & Africa, ASEAN, USA, and the UK.
CIO News is a proprietary of Mercadeo Multiventures Pvt Ltd.
